Erica L. Mayer, MD, PhD, on Metastatic Breast Cancer: New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy
2022 San Antonio Breast Cancer Symposium
Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and palbociclib; or fulvestrant, palbociclib, and avelumab. Combining palbociclib with fulvestrant beyond disease progression on a prior CDK4/6 inhibitor regimen did not improve progression-free survival compared with fulvestrant alone. A longer progression-free survival when a PD-L1 inhibitor was added to fulvestrant and palbociclib deserves further study. A baseline circulating tumor DNA analysis suggests that the potential benefit of palbociclib after progression on a prior CDK4/6 inhibitor may be influenced by ESR1 or PIK3CA status (Abstract GS3-06).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The combination of a CDK4/6 inhibitor and endocrine therapy has been a standard-of-care in the management of metastatic hormone receptor positive, HER2 negative breast cancer. Patients can do very well, but eventually resistance develops and progression. And then the question is, what do we do next? A big question has been, is it appropriate to continue CDK4/6 inhibition with a change in endocrine therapy or to stop CDK4/6 inhibition? The PACE Trial, which is a randomized phase 2 trial, was designed to address this question. Eligible patients for the PACE Trial had metastatic hormone receptor-positive/HER2-negative breast cancer, and had received a CDK4/6 inhibitor and endocrine therapy containing regimen, for at least six months of disease stability indicating endocrine resistance. Patients could have up to two lines of endocrine therapy, no prior fulvestrant and up to one prior line of chemotherapy.
Patients were randomized into one of three arms, fulvestrant alone, which we can think of as a control arm, fulvestrant with palbociclib, so continuation of a CDK4/6 inhibitor or a third arm of fulvestrant palbociclib and the PDL1 inhibitor, avelumab, a triplet combination which is based off of preclinical data. A total of 220 patients in the United States enrolled on the PACE Trial and results from this study which have been presented, demonstrated to us that continuation of the CDK4/6 inhibitor using palbociclib in combination with a change to fulvestrant, did not prolong progression-free survival compared to staying on fulvestrant alone. The median progression-free survival was 4.6 months with fulvestrant and palbociclib, and 4.8 months with fulvestrant alone. Interestingly, the triplet arm of fulvestrant, palbociclib and avelumab, had practically doubled progression-free survival at 8.1 months. Overall, this was a well-tolerated regimen. There were no unexpected toxicities and importantly in that triplet immunotherapy arm, there were no excessive immune related toxicities.
I think we can learn several things from this study. First of all, what we learned is that four patients who have been receiving a CDK4/6 inhibitor, which in this study was mostly palbociclib, if their disease progresses, continuing palbociclib beyond progression, was not shown to be helpful in the PACE Study, so we want to look into other options. But there are a lot of other options that are coming out for these patients, a wealth of options. This includes perhaps other CDK4/6 inhibitors such as ribociclib. There's palpolicib for patients with PIK3CA mutations. There's everolimus. Recently we've heard exciting data with capivasertib. We can offer oral surds, which are in development. There's PARP inhibitors for patients with BRCA mutations, so lots of different choices that are available for our patients and we look forward to more data that will help clarify what's the best option for patients in this situation.
Related Videos
The ASCO Post Staff
Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discusses an update of the SOFT trial, which showed that adding ovarian function suppression (OFS) to adjuvant tamoxifen for premenopausal women with estrogen receptor (ER)-positive breast cancer reduces the risk of recurrence. OFS enables the use of adjuvant aromatase inhibitors as an alternative to tamoxifen, which can further reduce recurrence of ER-positive, HER2-negative disease. Very young women—those younger than 35 years old—should be considered for OFS, according to Dr. Francis. In addition, tamoxifen alone is appropriate in women with low-risk clinical-pathologic features.
The ASCO Post Staff
Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses long-term clinical outcomes data that continue to show many women with early breast cancer can safely forgo chemotherapy, when guided by the 21-gene recurrence score result. The longer follow-up also showed that recurrences of breast cancer continue to occur years after the original diagnosis, although these recurrences were not prevented by chemotherapy use. Racial disparities were not explained by inequities in social determinants of health or treatment adherence, with Black women at higher risk of early recurrence within the first 5 years of diagnosis, but not later recurrence after 5 years (Abstract GS1-05).
The ASCO Post Staff
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the phase III EMERALD trial, the first study to demonstrate improved progression-free survival vs standard of care in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer with one to two prior lines of endocrine treatment, with or without one line of chemotherapy. This finding applied to all patients in the study, including the subgroup with ESR1 mutations (Abstract GS3-01).
The ASCO Post Staff
Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic patterns by race and age (Abstract PD1-08).
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant (Abstract GS3-04).
